PUBLISHER: IMARC | PRODUCT CODE: 1467619
PUBLISHER: IMARC | PRODUCT CODE: 1467619
The global single cell multiomics market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.0 Billion by 2032, exhibiting a growth rate (CAGR) of 15.4% during 2024-2032.
Single cell multiomics refers to the analysis of multiple types of molecules from an individual cell to gain insights regarding cellular diversity and heterogenity. It involves single cell genomics, proteomics, transcriptomics and metabolomics and is widely used in neurology, immunology, cell biology and oncology. Single cell multiomics aids in enhancing the understanding of population architectures and cellular properties of heterogeneous tissues. It utilizes single cell isolation and dispensing techniques to provide images of the molecular layers and complex biological structures. In comparison to the traditionally used live-cell fluorescence imaging techniques, single-cell multi-omics does not involve the destruction of cells for analysis and can measure multiple types of the molecule from a single cell. As a result, it is widely used across biotechnology and pharmaceutical organizations, hospitals, academics and research institutes and diagnostic laboratories.
The rising prevalence of chronic diseases, such as cancer and communicable viral diseases, is one of the key factors driving the growth of the market. Single cell multiomics provides a high-resolution landscape of cellular components in the tumors. Additionally, the widespread product adoption for visualization and analysis of cell heterogeneity, tumor micro-environment and antibody development are favoring the market growth. Moreover, various technological advancements, such as the development of single-cell isolation and barcoding technologies that enable deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA) and protein profiles to be measured at a single-cell resolution, are providing a thrust to the market growth. In line with this, significant growth in the pharmaceutical industry is positively impacting the market growth. Other factors, including the increasing adoption of personalized medicine for the treatment of genetic disorders, along with the extensive improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global single cell multiomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product type, technique, application and end user.
Single Cell Genomics
Single Cell Proteomics
Single Cell Transcriptomics
Single Cell Metabolomics
Consumables
Instruments
Software
Single-Cell Isolation and Dispensing
Single-Cell Analysis
Oncology
Cell Biology
Neurology
Others
Academic Institutes
Contract Research Organizations
Pharmaceutical and Biotech Companies
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 10x Genomics Inc., Becton Dickinson and Company, BGI Genomics (BGI Group), Bio-RAD Laboratories Inc., Fluidigm Corporation, Illumina Inc., Mission Bio, NanoCellect Biomedical, Nanostring Technologies Inc., Proteona, Takara Bio Inc. (Takara Holdings) and Thermo Fisher Scientific Inc.